|Bid||0.0000 x 2900|
|Ask||0.0000 x 1300|
|Day's Range||4.8000 - 5.2500|
|52 Week Range||2.6500 - 20.0500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Morrisville-based Liquidia has submitted its lead drug asset for potential approval by the U.S. Food and Drug Administration.
Ahead of a planned regulatory application early next year, a Triangle drugmaker has brought in more than $22 million.
Shares of Liquidia Technologies Inc. , a Durham, N.C.-based biotech, soared more than 70% Thursday before paring their gains, after Wedbush reiterated an outperform rating on the stock and said a $22.4 million fundraising will give the company the runway to keep going through the fourth quarter of 2020. The company said it sold 7.2 million shares at $3.13 a share in a private placement. Liquidia is aiming to leverage its proprietary Print technology to improve the clinical profile of approved active pharmaceutical ingredients, or APIs. The company's lead candidate called LIQ861 is a dry powder formulation of inhaled treprostinil to treat pulmonary arterial hypertension, or PAH. "In our view, LIQ861 has the potential to improve the therapeutic profile of treprostinil in treating PAH by safely delivering higher doses into the lung," Wedbush analysts led by Liana Moussatos wrote in a note to clients. The company is expecting to file a new drug application for the treatment in the first quarter of 2020. A second product candidate, LIQ865, a treatment for post-operative pain, is expected to enter phase 2 trials in 2020, said the note. Shares were last up 43% and have fallen 77% in the year to date, while the S&P 500 has gained 29%. Company plans to initiate a Phase 2 study in 2020.
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the third quarter. We get to see hedge funds' thoughts towards the market and […]
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Every investor in Liquidia Technologies, Inc. (NASDAQ:LQDA) should be aware of the most powerful shareholder groups...
Is Liquidia Technologies, Inc. (NASDAQ:LQDA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]